StreetInsider.com News Articles

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Tue, 03 Mar 2026 07:30:00 -0500

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the Citizens Life Sciences Conference on Tuesday, March 10^th, 2026 at 11:55 AM (ET).

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Tue, 03 Mar 2026 07:30:00 -0500

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Tue, 03 Mar 2026 07:30:00 -0500

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Tue, 03 Mar 2026 07:30:00 -0500

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Wed, 25 Feb 2026 07:30:00 -0500

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2^nd, 2026 at 11:50 AM (ET).

A live audio webcast will be accessible through the Investors section of the Company’s website

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Wed, 25 Feb 2026 07:30:00 -0500

A live audio webcast will be accessible through the Investors section of the Company’s website

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Wed, 25 Feb 2026 07:30:00 -0500

A live audio webcast will be accessible through the Investors section of the Company’s website

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

Wed, 25 Feb 2026 07:30:00 -0500

A live audio webcast will be accessible through the Investors section of the Company’s website

Form 8-K ANAVEX LIFE SCIENCES For: Feb 20

Wed, 25 Feb 2026 06:07:00 -0500

si-local-file:///var/storage/secattach/20260225/26054754.html

Form 8-K ANAVEX LIFE SCIENCES For: Feb 20

Wed, 25 Feb 2026 06:07:00 -0500

si-local-file:///var/storage/secattach/20260225/26054754.html

Anavex Life Sciences adds AMEOS Group CEO to board of directors

Mon, 23 Feb 2026 07:30:16 -0500

Anavex Life Sciences Corp. (NASDAQ: AVXL) announced the appointment of Dr. Axel Paeger to its board of directors. The clinical-stage biopharmaceutical company focuses on developing treatments for neurological disorders including Alzheimer's disease, Parkinson's disease, and Rett syndrome.

Dr. Paeger serves as chief executive officer of AMEOS Group, a healthcare provider based in Zürich, Switzerland. The company operates 85 hospitals and polyclinics along with 23 long-term care facilities across Europe. AMEOS Group employs 19,300 people and serves approximately 500,000 patients annually, according to the press release.

The AMEOS Group generates about one-third of its revenue from psychiatric hospitals and operates as a market

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Mon, 23 Feb 2026 07:30:00 -0500

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors.

“We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Dr. Paeger brings three decades

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Mon, 23 Feb 2026 07:30:00 -0500

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Mon, 23 Feb 2026 07:30:00 -0500

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Mon, 23 Feb 2026 07:30:00 -0500

Form 10-Q ANAVEX LIFE SCIENCES For: Dec 31

Mon, 09 Feb 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260209/25968797.html

Form 10-Q ANAVEX LIFE SCIENCES For: Dec 31

Mon, 09 Feb 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260209/25968797.html

Form 10-Q ANAVEX LIFE SCIENCES For: Dec 31

Mon, 09 Feb 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260209/25968798.html

Form 10-Q ANAVEX LIFE SCIENCES For: Dec 31

Mon, 09 Feb 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260209/25968798.html

Anavex Life Sciences (AVXL) Tops Q1 EPS by 6c

Mon, 09 Feb 2026 08:09:10 -0500

Anavex Life Sciences (NASDAQ: AVXL) reported Q1 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Anavex Life Sciences (AVXL) click here.

Form 8-K ANAVEX LIFE SCIENCES For: Feb 09

Mon, 09 Feb 2026 07:31:00 -0500

si-local-file:///var/storage/secattach/20260209/25964841.html

Form 8-K ANAVEX LIFE SCIENCES For: Feb 09

Mon, 09 Feb 2026 07:31:00 -0500

si-local-file:///var/storage/secattach/20260209/25964841.html

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Mon, 09 Feb 2026 07:30:00 -0500

Company to host a webcast today at 8:30 am Eastern Time

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first quarter of fiscal 2026.

“As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Mon, 09 Feb 2026 07:30:00 -0500

Company to host a webcast today at 8:30 am Eastern Time

“As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Mon, 09 Feb 2026 07:30:00 -0500

Company to host a webcast today at 8:30 am Eastern Time

“As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral